Theoretical Aspects of GPCR-Ligand Complex Pharmacology.

Over the past 50 years in pharmacology, an understanding of seven transmembrane (7TMR) function has been gained from the comparison of experimental data to receptor models. These models have been constructed from building blocks composed of systems consisting of series and parallel mass action binding reactions. Basic functions such as the the isomerization of receptors upon ligand binding, the sequential binding of receptors to membrane coupling proteins, and the selection of multiple receptor conformations have been combined in various ways to build receptor systems such as the ternary complex, extended ternary complex, and cubic ternary complex models for 7TMR function. Separately, the Black/Leff operational model has furnished an extremely valuable method of quantifying drug agonism. In the past few years, incorporation of the basic allosteric nature of 7TMRs has led to additional useful models of functional receptor allosteric mechanisms; these models yield valuable methods for quantifying allosteric effects. Finally, molecular dynamics has provided yet another new set of models describing the probability of formation of multiple receptor states; these radically new models are extremely useful in the prediction of functionally selective drug effects.

[1]  T. Costa,et al.  Agonist Efficacy and Aliosteric Models of Receptor Action a , 1997, Annals of the New York Academy of Sciences.

[2]  T. Kenakin,et al.  THE CUBIC TERNARY COMPLEX RECEPTOR-OCCUPANCY MODEL. II. UNDERSTANDING APPARENT AFFINITY , 1996 .

[3]  Guodong Liu,et al.  A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[4]  R. Neubig,et al.  Mechanism of agonist and antagonist binding to alpha 2 adrenergic receptors: evidence for a precoupled receptor-guanine nucleotide protein complex. , 1988, Biochemistry.

[5]  C. Thron On the analysis of pharmacological experiments in terms of an allosteric receptor model. , 1973, Molecular pharmacology.

[6]  Lisa Nguyen,et al.  Selectively Engaging β-Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac Performance , 2010, Journal of Pharmacology and Experimental Therapeutics.

[7]  J. Giraldo,et al.  On the fitting of binding data when receptor dimerization is suspected , 2008, British journal of pharmacology.

[8]  M. Bouxsein,et al.  Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2. , 2005, Endocrinology.

[9]  Andrea Iaboni,et al.  A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer , 2006, Nature Methods.

[10]  J. Black,et al.  Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[11]  P. Gmeiner,et al.  Histidine 6.55 Is a Major Determinant of Ligand-Biased Signaling in Dopamine D2L Receptor , 2011, Molecular Pharmacology.

[12]  D Rodbard,et al.  Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. , 1992, Molecular pharmacology.

[13]  L. Bohn,et al.  Morphine Side Effects in β-Arrestin 2 Knockout Mice , 2005, Journal of Pharmacology and Experimental Therapeutics.

[14]  J N Langley,et al.  On the Physiology of the Salivary Secretion , 1878, The Journal of physiology.

[15]  Shailesh N Mistry,et al.  Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics , 2015, British journal of pharmacology.

[16]  L. Potter,et al.  Anti-muscarinic toxins from Dendroaspis angusticeps. , 1996, Toxicon : official journal of the International Society on Toxinology.

[17]  Robyn L Stanfield,et al.  Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor , 2004, Journal of Virology.

[18]  J. Changeux,et al.  On the excitability and cooperativity of the electroplax membrane. , 1968, Proceedings of the National Academy of Sciences of the United States of America.

[19]  I. Charfi,et al.  Identifying ligand‐specific signalling within biased responses: focus on δ opioid receptor ligands , 2015, British journal of pharmacology.

[20]  B. Hudson,et al.  Complex Pharmacology of Novel Allosteric Free Fatty Acid 3 Receptor Ligands , 2014, Molecular Pharmacology.

[21]  R. Lefkowitz,et al.  A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. , 1980, The Journal of biological chemistry.

[22]  P. Sexton,et al.  Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening , 2010, Molecular Pharmacology.

[23]  B. Rovin,et al.  The Influence of CCL 3 L 1 Gene – Containing Segmental Duplications on HIV-1 / AIDS Susceptibility , 2009 .

[24]  Bernard Katz,et al.  Interaction at end-plate receptors between different choline derivatives , 1957, Proceedings of the Royal Society of London. Series B - Biological Sciences.

[25]  P. Wolynes,et al.  The energy landscapes and motions of proteins. , 1991, Science.

[26]  H. E. Umbarger,et al.  Evidence for a negative-feedback mechanism in the biosynthesis of isoleucine. , 1956, Science.

[27]  J. Black,et al.  An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation , 1985, British journal of pharmacology.

[28]  B. Katz,et al.  A study of the ‘desensitization’ produced by acetylcholine at the motor end‐plate , 1957, The Journal of physiology.

[29]  A Herz,et al.  Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Ellis,et al.  Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors. , 1999, Molecular pharmacology.

[31]  P. Molinoff,et al.  Characterization of radiolabeled agonist binding to beta-adrenergic receptors in mammalian tissues. , 1980, Journal of cyclic nucleotide research.

[32]  F. Ehlert The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. , 1985, Molecular pharmacology.

[33]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[34]  H. Frauenfelder,et al.  Conformational substates in proteins. , 1988, Annual review of biophysics and biophysical chemistry.

[35]  A. Minarini,et al.  Polymethylene tetraamines as muscarinic receptor probes. , 1989, Trends in pharmacological sciences.

[36]  Arthur Christopoulos,et al.  A simple method for quantifying functional selectivity and agonist bias. , 2012, ACS chemical neuroscience.

[37]  Irving Langmuir THE CONSTITUTION AND FUNDAMENTAL PROPERTIES OF SOLIDS AND LIQUIDS. PART I. SOLIDS. , 1916 .

[38]  B. Roth,et al.  Identification of Novel Functionally Selective κ-Opioid Receptor Scaffolds , 2014, Molecular Pharmacology.

[39]  J. Changeux,et al.  International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands , 2014, Pharmacological Reviews.

[40]  M. Brann,et al.  Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes. , 1991, Biochemical pharmacology.

[41]  P. Sexton,et al.  GPCR modulation by RAMPs. , 2006, Pharmacology & therapeutics.

[42]  T. Kenakin New Concepts in Drug Discovery: Collateral Efficacy and Permissive Antagonism , 2005, Nature Reviews Drug Discovery.

[43]  L. Johnson,et al.  A new allosteric site in glycogen phosphorylase b as a target for drug interactions. , 2000, Structure.

[44]  T. Oas,et al.  The structural distribution of cooperative interactions in proteins: analysis of the native state ensemble. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[45]  P. Sexton,et al.  Impact of species variability and ‘probe‐dependence’ on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor , 2011, British journal of pharmacology.

[46]  M. Glass,et al.  Allosteric Modulation of the Cannabinoid CB1 Receptor , 2017 .

[47]  Vsevolod V Gurevich,et al.  How and why do GPCRs dimerize? , 2008, Trends in pharmacological sciences.

[48]  Elliott M. Ross,et al.  Signal sorting and amplification through G protein-coupled receptors , 1989, Neuron.

[49]  J. M. Mathiesen,et al.  Identification of Indole Derivatives Exclusively Interfering with a G Protein-Independent Signaling Pathway of the Prostaglandin D2 Receptor CRTH2 , 2005, Molecular Pharmacology.

[50]  J P Changeux,et al.  Ivermectin: A Positive Allosteric Effector of the α7 Neuronal Nicotinic Acetylcholine Receptor , 1998 .

[51]  A. De Léan,et al.  The ternary complex model. Its properties and application to ligand interactions with the D2-dopamine receptor of the anterior pituitary gland. , 1984, Molecular pharmacology.

[52]  T. Kenakin Collateral efficacy as a pharmacological problem applied to new drug discovery , 2006, Expert opinion on drug discovery.

[53]  K. Mohr,et al.  Using a radioalloster to test predictions of the cooperativity model for gallamine binding to the allosteric site of muscarinic acetylcholine M(2) receptors. , 1999, Molecular pharmacology.

[54]  D. Koshland,et al.  The active site and enzyme action. , 2006, Advances in enzymology and related subjects of biochemistry.

[55]  A. Trkola,et al.  HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Burgen As Conformational changes and drug action. , 1981 .

[57]  T. Kenakin,et al.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. , 1995, Trends in pharmacological sciences.

[58]  A Karlin,et al.  On the application of "a plausible model" of allosteric proteins to the receptor for acetylcholine. , 1967, Journal of theoretical biology.

[59]  R P STEPHENSON,et al.  A MODIFICATION OF RECEPTOR THEORY , 1997, British journal of pharmacology and chemotherapy.

[60]  G. Milligan,et al.  The role of GPCR dimerisation/oligomerisation in receptor signalling. , 2006, Ernst Schering Foundation symposium proceedings.

[61]  J. Dumont,et al.  The two-step model of ligand-receptor interaction , 1977, Molecular and Cellular Endocrinology.

[62]  I. Langmuir THE CONSTITUTION AND FUNDAMENTAL PROPERTIES OF SOLIDS AND LIQUIDS , 1917 .

[63]  R. Lefkowitz,et al.  Distinct β-Arrestin- and G Protein-dependent Pathways for Parathyroid Hormone Receptor-stimulated ERK1/2 Activation* , 2006, Journal of Biological Chemistry.

[64]  Michel Bouvier,et al.  Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. , 2002, Annual review of pharmacology and toxicology.

[65]  N. Birdsall,et al.  Modification of the binding properties of muscarinic receptors by gallamine. , 1983, Molecular pharmacology.

[66]  J. Kemp,et al.  A novel mechanism of activity‐dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. , 1996, The Journal of physiology.

[67]  E. El-Fakahany,et al.  Modulation by certain conserved aspartate residues of the allosteric interaction of gallamine at the m1 muscarinic receptor. , 1992, The Journal of pharmacology and experimental therapeutics.

[68]  R. Goody,et al.  The original Michaelis constant: translation of the 1913 Michaelis-Menten paper. , 2011, Biochemistry.

[69]  Bryan L Roth,et al.  Galpha-subunits differentially alter the conformation and agonist affinity of kappa-opioid receptors. , 2008, Biochemistry.

[70]  C. Betsholtz,et al.  Islet amyloid polypeptide stimulates cyclic AMP accumulation via the porcine calcitonin receptor. , 1994, Biochemical and biophysical research communications.

[71]  T. Ramakrishnan,et al.  Biosynthesis of isoleucine and valine in Mycobacterium tuberculosis H37 Rv. , 1968, Archives of biochemistry and biophysics.

[72]  J. Olefsky,et al.  β-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic β cells , 2008, Proceedings of the National Academy of Sciences.

[73]  P. Cuatrecasas,et al.  The mobile receptor hypothesis and "cooperativity" of hormone binding. Application to insulin. , 1976, Biochimica et biophysica acta.

[74]  Terry Kenakin,et al.  Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. , 2007, Trends in pharmacological sciences.

[75]  A. Minton,et al.  A model for the interaction of muscarinic receptors, agonists, and two distinct effector substances. , 1990, Biochemistry.

[76]  T. Kenakin,et al.  The cubic ternary complex receptor-occupancy model. III. resurrecting efficacy. , 1996, Journal of theoretical biology.

[77]  T. Kenakin The potential for selective pharmacological therapies through biased receptor signaling , 2012, BMC Pharmacology and Toxicology.

[78]  M. Maguire,et al.  Relationship between the beta-adrenergic receptor and adenylate cyclase. , 1977, The Journal of biological chemistry.

[79]  C. Langmead,et al.  Quantitative Analysis Reveals Multiple Mechanisms of Allosteric Modulation of the mGlu5 Receptor in Rat Astroglia , 2011, Molecular Pharmacology.

[80]  Laurence J. Miller,et al.  Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery , 2010, Pharmacological Reviews.

[81]  N. Birdsall,et al.  The binding of antagonists to brain muscarinic receptors. , 1978, Molecular pharmacology.

[82]  David Colquhoun,et al.  The Relation between Classical and Cooperative Models for Drug Action , 1973 .

[83]  Clay W Scott,et al.  Evaluating Cellular Impedance Assays for Detection of GPCR Pleiotropic Signaling and Functional Selectivity , 2009, Journal of biomolecular screening.

[84]  G. Milligan A day in the life of a G protein‐coupled receptor: the contribution to function of G protein‐coupled receptor dimerization , 2008, British journal of pharmacology.

[85]  P. Morgan,et al.  The Cubic Ternary Complex ReceptorOccupancy Model I. Model Description , 1996 .

[86]  D. Lauffenburger,et al.  Epidermal growth factor receptor binding is not a simple one-step process. , 1989, The Journal of biological chemistry.

[87]  H. Mitsuya,et al.  Spirodiketopiperazine-Based CCR5 Inhibitor Which Preserves CC-Chemokine/CCR5 Interactions and Exerts Potent Activity against R5 Human Immunodeficiency Virus Type 1 In Vitro , 2004, Journal of Virology.

[88]  P. Cuatrecasas Membrane receptors. , 1974, Annual review of biochemistry.

[89]  P. Sexton,et al.  Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. , 2012, Endocrinology.

[90]  J P Changeux,et al.  On the cooperativity of biological membranes. , 1967, Proceedings of the National Academy of Sciences of the United States of America.

[91]  S. Rasmussen,et al.  Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.

[92]  F. Gasparini,et al.  CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. , 1999, Molecular pharmacology.

[93]  M. Caron,et al.  Regulation of beta-adrenergic receptors by guanyl-5'-yl imidodiphosphate and other purine nucleotides. , 1976, The Journal of biological chemistry.

[94]  A. VanDongen,et al.  G protein coupling of receptors to ionic channels and other effector systems. , 1990, British journal of clinical pharmacology.

[95]  T. Kenakin,et al.  The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor , 2005, Molecular Pharmacology.

[96]  P. Casellas,et al.  A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1 , 1997, The Journal of Biological Chemistry.

[97]  T. Kenakin,et al.  The Relative Activity of “Function Sparing” HIV-1 Entry Inhibitors on Viral Entry and CCR5 Internalization: Is Allosteric Functional Selectivity a Valuable Therapeutic Property? , 2009, Molecular Pharmacology.

[98]  R. Iyengar,et al.  Hormone receptor-mediated stimulation of adenylyl cyclase systems. Nucleotide effects and analysis in terms of a simple two-state model for the basic receptor-affected enzyme. , 1980, The Journal of biological chemistry.

[99]  A. Scheer,et al.  A Look at Receptor Efficacy. From the Signalling Network of the Cell to the Intramolecular Motion of the Receptor , 2000 .

[100]  A. Maelicke,et al.  New approach to drug therapy in Alzheimer's dementia Alfred Maelicke and Edson X. Albuquerque , 1996 .

[101]  N. Shankley,et al.  Interpretation of agonist affinity estimations: the question of distributed receptor states , 1990, Proceedings of the Royal Society of London. B. Biological Sciences.

[102]  Y. Imai Physiology of salivary secretion. , 1976, Frontiers of oral physiology.

[103]  Liang Tong,et al.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002 .

[104]  T. Oas,et al.  A statistical thermodynamic model of the protein ensemble. , 2006, Chemical reviews.

[105]  Michel Bouvier,et al.  Oligomerization of G-protein-coupled transmitter receptors , 2001, Nature Reviews Neuroscience.

[106]  F. Ciruela,et al.  G‐protein‐coupled receptor heteromers: function and ligand pharmacology , 2008, British journal of pharmacology.

[107]  P. Leff,et al.  Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. , 1998, Molecular pharmacology.

[108]  R. Lefkowitz,et al.  A β-Arrestin–Biased Agonist of the Parathyroid Hormone Receptor (PTH1R) Promotes Bone Formation Independent of G Protein Activation , 2009, Science Translational Medicine.

[109]  J. Galzi,et al.  A novel, conformation‐specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[110]  M. Maguire,et al.  An agonist-specific effect of guanine nucleotides on binding to the beta adrenergic receptor. , 1976, Molecular pharmacology.

[111]  Ariens Ej,et al.  Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory. , 1954 .

[112]  Jean Martinez,et al.  Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor , 2012, Proceedings of the National Academy of Sciences.

[113]  T. Kenakin Functional Selectivity and Biased Receptor Signaling , 2011, Journal of Pharmacology and Experimental Therapeutics.

[114]  J. Gaddum Theories of drug antagonism. , 1957, Pharmacological reviews.

[115]  Arthur Christopoulos,et al.  Signalling bias in new drug discovery: detection, quantification and therapeutic impact , 2012, Nature Reviews Drug Discovery.

[116]  P. Tauber Inhibition of lysosomal plasminogen activator activity in experimental shock. , 1973, Pharmacology.

[117]  D. Mackay Interpretation of relative potencies, relative efficacies and apparent affinity constants of agonist drugs estimated from concentration-response curves. , 1990, Journal of theoretical biology.

[118]  R. Lefkowitz,et al.  Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. , 1993, Trends in pharmacological sciences.

[119]  Thron Cd On the analysis of pharmacological experiments in terms of an allosteric receptor model. , 1973 .

[120]  E. Nisenbaum,et al.  Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists. , 2004, Biochemical Society transactions.

[121]  Frank McCormick,et al.  The GTPase superfamily: a conserved switch for diverse cell functions , 1990, Nature.

[122]  F. Ehlert,et al.  Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. , 1988, Molecular pharmacology.

[123]  F. Ehlert Analysis of Allosterism in Functional Assays , 2005, Journal of Pharmacology and Experimental Therapeutics.

[124]  H. Cheng,et al.  Dissociation constants of D- and L-lactoylcholines and related compounds at cholinergic receptors. , 1972, The Journal of pharmacology and experimental therapeutics.

[125]  R. Lefkowitz,et al.  A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. , 1993, The Journal of biological chemistry.